This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CG100649, Polmacoxib
Description: CG100649 is a novel and next generation non-steroidal anti-inflammatory drugs (NSAID) with a dual inhibition mechanism of binding COX-2 as well as carbonic anhydrases for improved cardiovascular, gastrointestinal, and renal safety profile.
CG100649's new mode of tissue-specific activity is designed to deliver sustained levels of drug to inflamed tissues while maintaining low systemic exposure by binding to carbonic anhydrase (CA) in red blood cells. CG100649 also inhibits COX-2 in the inflammatory joint, but not in the cardiovascular and gastrointestinal systems. Thus, CG100649 is highly efficacious in the control of inflammation and pain without showing typical side effects other NSAIDs have shown.
Additional information available to subscribers only: